Dyne Therapeutics, Inc. DYN

16.03 (0.48) (2.91%) as of 25 Sep
Market cap
$3.1B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

13.47 22.25 19.92 12.02
Net Debt/EBITDA
6.09 8.29 6.53 3.78
Debt/Assets
11.43% 12.55% 14.41% 21.48%
Debt/Equity
0.14 0.15 0.18 0.30
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.84 1.00 1.20 0.73
Capex/Depreciation
(2.55) (3.64) (0.79) (4.63)
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.64) (0.87) (0.88) (0.80)
Cash per Share
5.58 8.65 5.89 5.43
Shareholders Equity per Share
4.88 7.57 5.24 4.24
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.88 7.57 5.24 4.24
Free Cash Flow
(91.17) (112.32) (145.14) (131.80)
Working Capital
746.41 1,075.96 969.78 859.86
Capital Expenditures
(0.39) (0.48) (0.22) (1.51)
Net Current Asset Value
630.99 911.76 806.13 646.03
Other line items
Quick Ratio
13.23 21.94 18.97 11.51
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.64) (0.87) (0.88) (0.79)
Capex per Share
0.00 0.00 0.00 (0.01)
Average Payables
9.11 7.32 8.90 13.08
Average Assets
817.95 939.10 900.51 861.50
Average Common Equity
698.66 800.98 767.01 636.80
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates